| Project/Area Number |
22590753
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NOZU Tsukasa 旭川医科大学, 医学部, 准教授 (30312367)
KUMEI Shima 旭川医科大学, 大学病院, 医員 (00548969)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | PPARgamma / cancer / VEGF / 血管新生 / がん細胞増殖 |
|---|
| Research Abstract |
We have demonstrated that human cancer cell lines (PC-14 and RERF) express PPARgamma. Troglitazone, a PPARgamma ligand, dose-dependently inhibited cell growth, and upregulated mRNA and protein expression of VEGF. A inhibitor of VEGF significantly blocked the troglitazone-induced inhibition of cell growth, suggesting that VEGF may play a vital role in the inhibition of cell growth by troglitazone in human cance cells.
|
